Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.52 |
| ▸ | CA2 | P00918 | 9/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CA6 | P23280 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589703 | 0.87 | CA12 (0.54) | CA1CA2ESR1ESR2CA12 | |
| SCHEMBL3579502 | 0.86 | CA1 (0.58) | CA1CA2ESR1ESR2CA12 | |
| SCHEMBL14185182 | 0.84 | CA1 (0.49) | CA1CA2ESR1ESR2CA12 | |
| SCHEMBL4941071 | 0.83 | ESR1 (0.64) | ESR1ESR2GAAKDM4EALDH1A1 | |
| SCHEMBL14185208 | 0.81 | CA1 (0.46) | CA1CA2ESR1ESR2CA12 | |
| SCHEMBL14185196 | 0.80 | KDM4E (0.57) | CA1CA2ESR1CA12CA9 | |
| SCHEMBL3578968 | 0.80 | CA1 (0.50) | CA1CA2ESR1ESR2CA12 | |
| SCHEMBL14185223 | 0.79 | ESR1 (0.48) | ESR1ESR2CA12CA9GAA | |
| SCHEMBL14185202 | 0.79 | CA12 (0.54) | CA1CA2ESR1ESR2CA12 | |
| SCHEMBL3589603 | 0.79 | GAA (0.45) | CA1CA2CA12CA9CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732435-B2 | Chromone derivatives useful as antagonists of VR1 receptors | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-20080312316-A1 | Chromone Derivatives Useful as Antagonists of Vr1 Receptors | CULSHAW ANDREW JAMES | 2008-12-18 | — | — | US | disclosed |
| EP-1963334-A1 | CHROMONE DERIVATIVES USEFUL AS ANTAGONISTS OF VR1 RECEPTORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065888-A1 | CHROMONE DERIVATIVES USEFUL AS ANTAGONISTS OF VR1 RECEPTORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312316-A1 | Chromone Derivatives Useful as Antagonists of Vr1 Receptors | VRK1, VRK2, ARRB1 | CA1 2466/4885CA2 628/4885ESR1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.